Ampio to begin first clinical trial in COVID-19 program

Ampio to begin first clinical trial in COVID-19 program

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19"). The U.S. Food and Drug... Read More

Monday June 22, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio provides update on COVID research program

Ampio provides update on COVID research program

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE),a biopharmaceutical company focused on the advancement of immunology-basedtherapies for prevalentinflammatory conditions, announced... Read More

Tuesday May 26, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio reports acceptance of publication on potential benefits of nebulized Ampion for COVID patients

Ampio reports acceptance of publication on potential benefits of nebulized Ampion for COVID patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE),a biopharmaceutical company focused on the development of immunology-based therapies for prevalent inflammatory conditions,... Read More

Tuesday May 12, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS

Ampio prepares FDA protocol to study Ampion as treatment for COVID-19 Acute Respiratory Distress

Ampio prepares FDA protocol to study Ampion as treatment for COVID-19 Acute Respiratory Distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it is preparing an expanded access FDA protocolto study potential benefit of nebulized treatment with Ampion in SARS-Cov-2... Read More

Wednesday March 25, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio updates regulatory status for Ampion drug

Ampio updates regulatory status for Ampion drug

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it met with the FDA on Dec. 12 to discuss final guidance to achieve regulatory approval for its osteoarthritis drug Ampion.... Read More

Friday December 14, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio provides update on Ampion regulatory review

Ampio provides update on Ampion regulatory review

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reports favorable regulatory and peer-review on the status of Ampion, the companys drug for osteoarthritis of the knee. ... Read More

Tuesday November 27, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio updates Ampion regulatory progress

Ampio updates Ampion regulatory progress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion... Read More

Monday November 12, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso